{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:44:50Z","timestamp":1774266290479,"version":"3.50.1"},"reference-count":21,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Current therapies have changed systemic vasculitis from a disease with a high rate of mortality to a chronic curable condition. A limited percentage of patients either remains refractory to conventional treatment or experiences dose-limiting side effects. &lt;i&gt;Methods:&lt;\/i&gt; 11 patients (4 affected by idiopathic systemic microscopic polyangiitis, 5 by Wegener\u2019s granulomatosis, and 2 by Churg-Strauss syndrome) intolerant or refractory to conventional therapies including cyclophosphamide were enrolled. All patients received rituximab as a rescue therapy and were followed for 30\u201354 months. Following rituximab administration, immunosuppressive drugs were rapidly tapered and no immunosuppressive maintenance therapy was given. &lt;i&gt;Results:&lt;\/i&gt; Significant decreases in levels of serum creatinine, proteinuria, erythrocyte sedimentation rate, C-reactive protein, and ANCA titers were observed during the follow-up (at least 30 months after rituximab administration). Arthralgia and weakness rapidly disappeared in all patients. Out of 7 patients, 5 reported a decrease in the degree of paresthesia and in the electrophysiologic parameters. Six months after rituximab administration the mean dose of prednisone was 5.5 mg\/day. &lt;i&gt;Conclusion:&lt;\/i&gt; In this sample of patients with systemic vasculitis who were refractory or intolerant to more conventional treatment, rituximab proved to be safe and effective in a long-term follow-up, and showed steroid- and immunosuppressive-sparing effects allowing the persistence of long-lasting remissions without maintenance therapy.<\/jats:p>","DOI":"10.1159\/000329535","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T17:15:58Z","timestamp":1310145358000},"page":"175-180","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis"],"prefix":"10.1159","volume":"34","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Alpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Menegatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.clim.2005.08.006"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146%2Fannurev.immunol.24.021605.090517"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0909169"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0909905"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfh469"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007%2Fs12016-007-8019-0"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00415-009-5072-z"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136%2Fard.2008.101279"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080%2F03009740802668554"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa020286"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa041884"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002%2Fart.21142"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053%2Fberh.2000.0141"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164%2Frccm.200507-1144OC"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2796.2005.01494.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136%2Fard.2004.029694"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080%2F02813430510015269"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136%2Fard.2005.044420"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.it.2008.03.001"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038%2Fnri1334"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1196%2Fannals.1423.028"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329535","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:20:33Z","timestamp":1745432433000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000329535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,8,1]]},"published-print":{"date-parts":[[2011,8,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000329535","archive":["Portico"],"relation":{},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}